Introduction You hear the words "glioblastoma" and the statistics hit immediately. Most people with this type of brain cancer survive for less than 2 years. Standard radiation and temozolomide chemotherapy can buy time, but the tumor nearly always returns. That grim reality is what makes the shift toward personalized immunotherapy matter in 2026. Instead of a one-size-fits-all poison, researchers now engineer treatments that match your tumor's specific genetic mutations, trai